What does Reopro treat?

Reopro (Abciximab) may be used to treat unstable angina, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.

Is there a coupon or discount for Reopro?

pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Reopro. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.

Reopro is marketed by Centocor Inc. You can see Centocor Inc's full profile, rating, and other products on pharmaranks.

Is Reopro a brand-name or generic drug?

Reopro is a brand-name product with the active ingredient Abciximab.

Is Reopro available over the counter?

No. Reopro is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.

What forms does Reopro come in?

Reopro is currently marketed as injectable, per the FDA's National Drug Code Directory.

Is Reopro FDA-registered?

Reopro is on record with the U.S. FDA under application number BLA103575. You can verify this on its official FDA label.

reopro

Reopro (Abciximab) is a medication used to treat Unstable Angina.

Abciximab · by Centocor Inc

Not yet rated· sourced from the FDA label

Rated against independent regulatory sources·Last updated June 7, 2026·How we rate

Verified againstopenFDANIH DailyMedRxClass

See alternatives →

Key facts

Active ingredient: Abciximab
Form: Injectable
Strength: Abciximab 2MG/ML
Type: Prescription (Rx)
Brand or generic: Brand-name
May treat: unstable angina
Manufacturer: Centocor Inc
FDA application: BLA103575

May treat (source: NIH RxClass)

unstable angina

Dosage forms

Injectable

The forms currently marketed in the U.S., per the FDA National Drug Code Directory.

Ways to save

Ask for the generic

Same active ingredient, far cheaper. Is there a generic? →

Request a 90-day supply

Bulk fills usually lower the per-dose price vs monthly refills.

Use copay cards

Manufacturer copay cards & patient-assistance programs — especially for brand drugs.

Compare alternatives

A same-class option may cost less. See alternatives →

Frequently asked questions

What does Reopro treat?: Reopro (Abciximab) may be used to treat unstable angina, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
Is there a coupon or discount for Reopro?: pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Reopro. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
Who makes Reopro?: Reopro is marketed by Centocor Inc. You can see Centocor Inc's full profile, rating, and other products on pharmaranks.
Is Reopro a brand-name or generic drug?: Reopro is a brand-name product with the active ingredient Abciximab.
Is Reopro available over the counter?: No. Reopro is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
What forms does Reopro come in?: Reopro is currently marketed as injectable, per the FDA's National Drug Code Directory.
Is Reopro FDA-registered?: Reopro is on record with the U.S. FDA under application number BLA103575. You can verify this on its official FDA label.

Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.

What people report to the FDA about ABCIXIMAB

The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 1,156 reports naming ABCIXIMAB — the active ingredient in Reopro, and the FDA flagged 82% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:

myocardial infarction252 reports
thrombocytopenia90 reports
coronary artery stenosis75 reports
haemorrhage74 reports
coronary artery disease64 reports
gastrointestinal haemorrhage54 reports
incorrect route of drug administration47 reports
ventricular fibrillation46 reports

Read these as a signal, not a rate. A report does not mean ABCIXIMAB caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.

Source: openFDA drug/event (FAERS), retrieved September 25, 2026.